47 related articles for article (PubMed ID: 19132193)
41. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
42. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
44. Pharmacotherapy in the critically ill obese patient.
Medico CJ; Walsh P
Crit Care Clin; 2010 Oct; 26(4):679-88. PubMed ID: 20970057
[TBL] [Abstract][Full Text] [Related]
45. Individualised medicine: why we need Bayesian dosing.
Donagher J; Martin JH; Barras MA
Intern Med J; 2017 May; 47(5):593-600. PubMed ID: 28503880
[TBL] [Abstract][Full Text] [Related]
46.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
47.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
